NCT01954563View on ClinicalTrials.gov

Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Tuberculosis
Interventions
BIOLOGICAL

MVA85A

Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01954563 - Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity | Biotech Hunter | Biotech Hunter